Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by tuesdaynightridon Jun 19, 2014 7:45am

237 Views

Post# 22674146

RE:RE:Rat model validation was next milestone/catalyst.

Regarding Gustoes Milestone 5 (securing agreement with big Pharma), depending on how quickly news is disseminated from Ph1/2, there may actually begin a bidding war in 2015.
Patent expiration and ineffective treatments to date means the shelves are bare at many Pharma.
This assumes they do start in 1st q 2015 and are able to identify and enroll 30 patients within say a 4-5 month time frame. It is also my understanding that these patients have localized bladder cancer...
not metastatic.

Hence my earlier question: how quickly is news allowed to be communicated in a ph1/2 trial when
there is no randomized population (ie all 30 patients receive the same treatment).
What are the rules?

Bullboard Posts

5 steps to mastering risk management in the stock market